首页 > 最新文献

British Journal of Surgery最新文献

英文 中文
Disease-specific survival outcomes for patients after locoregional treatment for ductal carcinoma in situ: observational cohort study. 导管原位癌局部治疗后患者的疾病特异性生存结果:观察性队列研究。
IF 8.6 1区 医学 Q1 SURGERY Pub Date : 2024-08-30 DOI: 10.1093/bjs/znae198
Sabrina M Wang, Yan Li, Amanda Nash, Yi Ren, Samantha M Thomas, Amanda B Francescatti, Anne Barber, Thomas Lynch, Elizabeth S Frank, Lars J Grimm, Alastair M Thompson, Ann H Partridge, Terry Hyslop, E Shelley Hwang, Marc D Ryser

Background: Breast-conserving surgery alone, breast-conserving surgery with adjuvant radiation treatment, and mastectomy are guideline-concordant treatments for ductal carcinoma in situ. The aim of this study was to compare survival outcomes between these treatment options.

Methods: A stratified random sample of patients diagnosed with pure ductal carcinoma in situ between 2008 and 2014 was selected from 1330 sites in the USA. Data on diagnosis, treatment, and follow-up were abstracted by local cancer registrars. Population-averaged marginal estimates of disease-specific survival and overall survival for breast-conserving surgery alone, breast-conserving surgery with radiation treatment, and mastectomy were obtained by combining sampling and overlap weights.

Results: A total of 18 442 women were included, with a median follow-up of 67.8 (interquartile range 46.1-93.5) months. A total of 35 women died from breast cancer, at a median age of 62 (interquartile range 50-74) years. Population-averaged 8-year rates of disease-specific survival were 99.6% or higher for all treatment groups, with no significant differences between groups (breast-conserving surgery alone versus breast-conserving surgery with radiation treatment, HR 1.19 (95% c.i. 0.29 to 4.85); and mastectomy versus breast-conserving surgery with radiation treatment, HR 1.74 (95% c.i. 0.53 to 5.72). There was no difference in overall survival between the patients who underwent a mastectomy and the patients who underwent breast-conserving surgery with radiation treatment (HR 1.09 (95% c.i. 0.83 to 1.43)). Patients who underwent breast-conserving surgery alone had lower overall survival compared with the patients who underwent breast-conserving surgery with radiation treatment (HR 1.29 (95% c.i. 1.00 to 1.67)). This survival difference vanished for all but one subgroup, namely patients less than 65 years (HR 1.86 (95% c.i. 1.15 to 3.00)).

Conclusion: There was no statistically significant difference in disease-specific survival between women operated with breast-conserving surgery alone, breast-conserving surgery with radiation treatment, or mastectomy for ductal carcinoma in situ. Given the low absolute risk of disease-specific mortality, these results provide confidence in offering individualized locoregional treatment without fear of compromising survival.

背景:单纯保乳手术、保乳手术加辅助放射治疗以及乳房切除术是乳腺导管原位癌的指导性一致治疗方法。本研究旨在比较这些治疗方案的生存结果:方法:从美国 1330 个医疗机构中选取 2008 年至 2014 年期间确诊为纯导管原位癌的患者作为分层随机样本。诊断、治疗和随访数据由当地癌症登记员抽取。结合抽样和重叠权重,得出了单纯保乳手术、保乳手术加放射治疗和乳房切除术的疾病特异性生存率和总生存率的人群平均边际估计值:研究共纳入了 18 442 名妇女,中位随访时间为 67.8 个月(四分位间范围为 46.1-93.5 个月)。共有 35 名妇女死于乳腺癌,中位年龄为 62 岁(四分位数间距为 50-74)。所有治疗组的人群平均 8 年疾病特异性生存率均在 99.6% 或以上,组间无显著差异(单纯保乳手术与保乳手术加放射治疗相比,HR 为 1.19(95% 置信区间为 0.29 至 4.85);乳房切除术与保乳手术加放射治疗相比,HR 为 1.74(95% 置信区间为 0.53 至 5.72)。接受乳房切除术的患者与接受放射治疗的保乳手术患者的总生存率没有差异(HR 1.09(95% 置信区间:0.83 至 1.43))。与接受放射治疗的保乳手术患者相比,单纯接受保乳手术的患者总生存率较低(HR 1.29(95% 置信区间:1.00 至 1.67))。除了一个亚组,即小于65岁的患者(HR 1.86 (95% c.i. 1.15 to 3.00))外,其他所有亚组的生存率差异都消失了:结论:单纯保乳手术、保乳手术加放射治疗或乳腺切除术治疗乳腺导管原位癌的妇女在疾病特异性生存率方面没有明显的统计学差异。鉴于疾病特异性死亡率的绝对风险较低,这些结果为提供个体化的局部治疗提供了信心,而不必担心影响生存率。
{"title":"Disease-specific survival outcomes for patients after locoregional treatment for ductal carcinoma in situ: observational cohort study.","authors":"Sabrina M Wang, Yan Li, Amanda Nash, Yi Ren, Samantha M Thomas, Amanda B Francescatti, Anne Barber, Thomas Lynch, Elizabeth S Frank, Lars J Grimm, Alastair M Thompson, Ann H Partridge, Terry Hyslop, E Shelley Hwang, Marc D Ryser","doi":"10.1093/bjs/znae198","DOIUrl":"10.1093/bjs/znae198","url":null,"abstract":"<p><strong>Background: </strong>Breast-conserving surgery alone, breast-conserving surgery with adjuvant radiation treatment, and mastectomy are guideline-concordant treatments for ductal carcinoma in situ. The aim of this study was to compare survival outcomes between these treatment options.</p><p><strong>Methods: </strong>A stratified random sample of patients diagnosed with pure ductal carcinoma in situ between 2008 and 2014 was selected from 1330 sites in the USA. Data on diagnosis, treatment, and follow-up were abstracted by local cancer registrars. Population-averaged marginal estimates of disease-specific survival and overall survival for breast-conserving surgery alone, breast-conserving surgery with radiation treatment, and mastectomy were obtained by combining sampling and overlap weights.</p><p><strong>Results: </strong>A total of 18 442 women were included, with a median follow-up of 67.8 (interquartile range 46.1-93.5) months. A total of 35 women died from breast cancer, at a median age of 62 (interquartile range 50-74) years. Population-averaged 8-year rates of disease-specific survival were 99.6% or higher for all treatment groups, with no significant differences between groups (breast-conserving surgery alone versus breast-conserving surgery with radiation treatment, HR 1.19 (95% c.i. 0.29 to 4.85); and mastectomy versus breast-conserving surgery with radiation treatment, HR 1.74 (95% c.i. 0.53 to 5.72). There was no difference in overall survival between the patients who underwent a mastectomy and the patients who underwent breast-conserving surgery with radiation treatment (HR 1.09 (95% c.i. 0.83 to 1.43)). Patients who underwent breast-conserving surgery alone had lower overall survival compared with the patients who underwent breast-conserving surgery with radiation treatment (HR 1.29 (95% c.i. 1.00 to 1.67)). This survival difference vanished for all but one subgroup, namely patients less than 65 years (HR 1.86 (95% c.i. 1.15 to 3.00)).</p><p><strong>Conclusion: </strong>There was no statistically significant difference in disease-specific survival between women operated with breast-conserving surgery alone, breast-conserving surgery with radiation treatment, or mastectomy for ductal carcinoma in situ. Given the low absolute risk of disease-specific mortality, these results provide confidence in offering individualized locoregional treatment without fear of compromising survival.</p>","PeriodicalId":136,"journal":{"name":"British Journal of Surgery","volume":null,"pages":null},"PeriodicalIF":8.6,"publicationDate":"2024-08-30","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142102483","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Neoadjuvant therapy with peptide receptor radionuclide therapy for pancreatic neuroendocrine tumours. 胰腺神经内分泌肿瘤的肽受体放射性核素新辅助疗法。
IF 8.6 1区 医学 Q1 SURGERY Pub Date : 2024-08-30 DOI: 10.1093/bjs/znae183
Julie Hallet, Kjetil Søreide
{"title":"Neoadjuvant therapy with peptide receptor radionuclide therapy for pancreatic neuroendocrine tumours.","authors":"Julie Hallet, Kjetil Søreide","doi":"10.1093/bjs/znae183","DOIUrl":"10.1093/bjs/znae183","url":null,"abstract":"","PeriodicalId":136,"journal":{"name":"British Journal of Surgery","volume":null,"pages":null},"PeriodicalIF":8.6,"publicationDate":"2024-08-30","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11364144/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142102529","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Bowel cleansing, dysbiosis, and postoperative infection: the dots are starting to connect. 肠道清洁、菌群失调和术后感染:这些点开始联系起来。
IF 8.6 1区 医学 Q1 SURGERY Pub Date : 2024-08-30 DOI: 10.1093/bjs/znae207
John C Alverdy
{"title":"Bowel cleansing, dysbiosis, and postoperative infection: the dots are starting to connect.","authors":"John C Alverdy","doi":"10.1093/bjs/znae207","DOIUrl":"https://doi.org/10.1093/bjs/znae207","url":null,"abstract":"","PeriodicalId":136,"journal":{"name":"British Journal of Surgery","volume":null,"pages":null},"PeriodicalIF":8.6,"publicationDate":"2024-08-30","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142118510","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Emergency care of metabolic bariatric surgery patients. 代谢性减肥手术患者的紧急护理。
IF 9.6 1区 医学 Q1 SURGERY Pub Date : 2024-08-30 DOI: 10.1093/bjs/znae233
Roxanna Zakeri,Ellen Andersson,Cynthia M Borg,Ronald S L Liem
{"title":"Emergency care of metabolic bariatric surgery patients.","authors":"Roxanna Zakeri,Ellen Andersson,Cynthia M Borg,Ronald S L Liem","doi":"10.1093/bjs/znae233","DOIUrl":"https://doi.org/10.1093/bjs/znae233","url":null,"abstract":"","PeriodicalId":136,"journal":{"name":"British Journal of Surgery","volume":null,"pages":null},"PeriodicalIF":9.6,"publicationDate":"2024-08-30","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142170850","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Inequalities for women diagnosed with distal arch and descending thoracic aortic aneurysms: results from the Effective Treatments for Thoracic Aortic Aneurysms (ETTAA) cohort study. 被诊断出患有远端拱形和降主动脉瘤的女性的不平等:胸主动脉瘤有效治疗(ETTAA)队列研究的结果。
IF 8.6 1区 医学 Q1 SURGERY Pub Date : 2024-08-02 DOI: 10.1093/bjs/znae185
Anna L Pouncey, Dhvni Patel, Carol Freeman, Priya Sastry, Colin Bicknell, Stephen R Large, Linda D Sharples

Background: Women with thoracic aortic aneurysms within the arch or descending thoracic aorta have poorer survival than men. Sex differences in relative thoracic aortic aneurysm size may account for some of the discrepancy. The aim of this study was to explore whether basing clinical management on aneurysm size index (maximum aneurysm diameter/body surface area) rather than aneurysm size can restore equality of survival by sex.

Methods: The Effective Treatments for Thoracic Aortic Aneurysms (ETTAA; ISRCTN04044627) study was a prospective, observational cohort study. Adults referred to National Health Service hospitals in England with new/existing arch or descending thoracic aorta aneurysms greater than or equal to 4 cm in diameter were followed from March 2014 to March 2022. Baseline characteristics and survival to intervention and overall were compared for men and women. Survival models were used to assess the association between all-cause survival and sex, with and without adjustment for aneurysm diameter or aneurysm size index.

Results: A total of 886 thoracic aortic aneurysm patients were recruited: 321 (36.2%) women and 565 (63.8%) men. The mean(s.d.) aneurysm diameter was the same for women and men (5.7(1.1) versus 5.7(1.2) cm respectively; P = 0.751), but the mean(s.d.) aneurysm size index was greater for women than for men (3.32(0.80) versus 2.83(0.63) respectively; P < 0.001). Women had significantly worse survival without intervention: 110 (34.3%) women and 135 (23.9%) men (log rank test, P < 0.001). All-cause mortality remained greater for women after adjustment for diameter (HR 1.65 (95% c.i. 1.35 to 2.02); P < 0.001), but was attenuated after adjustment for aneurysm size index (HR 1.11 (95% c.i. 0.89 to 1.38); P = 0.359). Similar results were found for all follow-up, with or without intervention, and findings were consistent for descending thoracic aorta aneurysms alone.

Conclusion: Guidelines for referral to specialist services should consider including aneurysm size index rather than diameter to reduce inequity due to patient sex.

背景:患有胸主动脉弓或降主动脉内胸主动脉瘤的女性存活率低于男性。胸主动脉瘤相对大小的性别差异可能是造成这种差异的部分原因。本研究旨在探讨根据动脉瘤大小指数(动脉瘤最大直径/体表面积)而非动脉瘤大小进行临床管理是否能恢复性别生存率平等:胸主动脉瘤的有效治疗(ETTAA;ISRCTN04044627)研究是一项前瞻性观察队列研究。2014年3月至2022年3月期间,对转诊至英格兰国民健康服务医院、患有直径大于或等于4厘米的新发/存在的弓形或降主动脉瘤的成人进行了随访。比较了男性和女性的基线特征、干预后存活率和总存活率。在对动脉瘤直径或动脉瘤大小指数进行调整或未进行调整的情况下,使用生存模型评估全因生存率与性别之间的关系:结果:共招募了 886 名胸主动脉瘤患者:其中女性 321 人(36.2%),男性 565 人(63.8%)。女性和男性动脉瘤的平均(s.d.)直径相同(分别为 5.7(1.1) cm 对 5.7(1.2) cm;P = 0.751),但女性动脉瘤的平均(s.d.)大小指数大于男性(分别为 3.32(0.80) cm 对 2.83(0.63) cm;P < 0.001)。女性在未接受干预的情况下存活率明显较低:女性为 110 人(34.3%),男性为 135 人(23.9%)(对数秩检验,P < 0.001)。根据直径进行调整后,女性的全因死亡率仍然更高(HR 1.65(95% 置信区间:1.35 至 2.02);P < 0.001),但根据动脉瘤大小指数进行调整后,女性的全因死亡率有所降低(HR 1.11(95% 置信区间:0.89 至 1.38);P = 0.359)。无论是否进行干预,所有随访结果相似,仅降主动脉瘤的随访结果一致:结论:专科服务转诊指南应考虑纳入动脉瘤大小指数而非直径,以减少因患者性别造成的不平等。
{"title":"Inequalities for women diagnosed with distal arch and descending thoracic aortic aneurysms: results from the Effective Treatments for Thoracic Aortic Aneurysms (ETTAA) cohort study.","authors":"Anna L Pouncey, Dhvni Patel, Carol Freeman, Priya Sastry, Colin Bicknell, Stephen R Large, Linda D Sharples","doi":"10.1093/bjs/znae185","DOIUrl":"10.1093/bjs/znae185","url":null,"abstract":"<p><strong>Background: </strong>Women with thoracic aortic aneurysms within the arch or descending thoracic aorta have poorer survival than men. Sex differences in relative thoracic aortic aneurysm size may account for some of the discrepancy. The aim of this study was to explore whether basing clinical management on aneurysm size index (maximum aneurysm diameter/body surface area) rather than aneurysm size can restore equality of survival by sex.</p><p><strong>Methods: </strong>The Effective Treatments for Thoracic Aortic Aneurysms (ETTAA; ISRCTN04044627) study was a prospective, observational cohort study. Adults referred to National Health Service hospitals in England with new/existing arch or descending thoracic aorta aneurysms greater than or equal to 4 cm in diameter were followed from March 2014 to March 2022. Baseline characteristics and survival to intervention and overall were compared for men and women. Survival models were used to assess the association between all-cause survival and sex, with and without adjustment for aneurysm diameter or aneurysm size index.</p><p><strong>Results: </strong>A total of 886 thoracic aortic aneurysm patients were recruited: 321 (36.2%) women and 565 (63.8%) men. The mean(s.d.) aneurysm diameter was the same for women and men (5.7(1.1) versus 5.7(1.2) cm respectively; P = 0.751), but the mean(s.d.) aneurysm size index was greater for women than for men (3.32(0.80) versus 2.83(0.63) respectively; P < 0.001). Women had significantly worse survival without intervention: 110 (34.3%) women and 135 (23.9%) men (log rank test, P < 0.001). All-cause mortality remained greater for women after adjustment for diameter (HR 1.65 (95% c.i. 1.35 to 2.02); P < 0.001), but was attenuated after adjustment for aneurysm size index (HR 1.11 (95% c.i. 0.89 to 1.38); P = 0.359). Similar results were found for all follow-up, with or without intervention, and findings were consistent for descending thoracic aorta aneurysms alone.</p><p><strong>Conclusion: </strong>Guidelines for referral to specialist services should consider including aneurysm size index rather than diameter to reduce inequity due to patient sex.</p>","PeriodicalId":136,"journal":{"name":"British Journal of Surgery","volume":null,"pages":null},"PeriodicalIF":8.6,"publicationDate":"2024-08-02","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11293951/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141873662","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
European Society of Endocrine Surgeons (ESES) consensus statement on advanced thyroid cancer: definitions and management. 欧洲内分泌外科医生学会(ESES)关于晚期甲状腺癌:定义和管理的共识声明。
IF 8.6 1区 医学 Q1 SURGERY Pub Date : 2024-08-02 DOI: 10.1093/bjs/znae199
Marco Raffaelli, Nikolaos Voloudakis, Marcin Barczynski, Katrin Brauckhoff, Cosimo Durante, Joaquin Gomez-Ramirez, Ioannis Koutelidakis, Kerstin Lorenz, Ozer Makay, Gabriele Materazzi, Rumen Pandev, Gregory W Randolph, Neil Tolley, Menno Vriens, Thomas Musholt
{"title":"European Society of Endocrine Surgeons (ESES) consensus statement on advanced thyroid cancer: definitions and management.","authors":"Marco Raffaelli, Nikolaos Voloudakis, Marcin Barczynski, Katrin Brauckhoff, Cosimo Durante, Joaquin Gomez-Ramirez, Ioannis Koutelidakis, Kerstin Lorenz, Ozer Makay, Gabriele Materazzi, Rumen Pandev, Gregory W Randolph, Neil Tolley, Menno Vriens, Thomas Musholt","doi":"10.1093/bjs/znae199","DOIUrl":"10.1093/bjs/znae199","url":null,"abstract":"","PeriodicalId":136,"journal":{"name":"British Journal of Surgery","volume":null,"pages":null},"PeriodicalIF":8.6,"publicationDate":"2024-08-02","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11331340/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141998995","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Role of Lugol solution before total thyroidectomy for Graves' disease: randomized clinical trial. 巴塞杜氏病甲状腺全切除术前使用鲁戈尔溶液的作用:随机临床试验。
IF 8.6 1区 医学 Q1 SURGERY Pub Date : 2024-08-02 DOI: 10.1093/bjs/znae196
Donatella Schiavone, Filippo Crimì, Giulio Cabrelle, Gianmaria Pennelli, Diana Sacchi, Caterina Mian, Francesca Torresan, Maurizio Iacobone

Background: Lugol solution is often administered to patients with Graves' disease before surgery. The aim is to reduce thyroid vascularization and surgical morbidity, but its real effectiveness remains controversial. The present study was designed to evaluate the effects of preoperative Lugol solution on thyroid vascularization and surgical morbidity in patients with Graves' disease undergoing total thyroidectomy.

Methods: Fifty-six patients undergoing total thyroidectomy for Graves' disease were randomly assigned to receive 7 days of Lugol treatment (Lugol+ group, 29) or no Lugol treatment (LS- group, 27) before surgery in this single-centre and single-blinded trial. Preoperative hormone and colour Doppler ultrasonographic data for assessing thyroid vascularization were collected 8 days before surgery (T0) and on the day of surgery (T1). The primary outcome was intraoperative and postoperative blood loss. Secondary outcomes included duration of surgery, thyroid function, morbidity, vascularization, and microvessel density at final pathology.

Results: No differences in demographic, preoperative hormone or ultrasonographic data were found between LS+ and LS- groups at T0. At T1, free tri-iodothyronine (FT3) and free thyroxine (FT4) levels were significantly reduced compared with T0 values in the LS+ group, whereas no such variation was observed in the LS- group. No differences between T0 and T1 were found for ultrasonographic vascularization in either group, nor did the histological findings differ. There were no significant differences between the LS+ and LS- groups concerning intraoperative/postoperative blood loss (median 80.5 versus 94 ml respectively), duration of surgery (75 min in both groups) or postoperative morbidity.

Conclusion: Lugol solution significantly reduces FT3 and FT4 levels in patients undergoing surgery for Graves' disease, but does not decrease intraoperative/postoperative blood loss, thyroid vascularization, duration of surgery or postoperative morbidity.

Registration number: NCT05784792 (https://www.clinicaltrials.gov).

背景:巴塞杜氏病患者在手术前通常会使用卢戈溶液。其目的是减少甲状腺血管扩张和手术发病率,但其实际效果仍存在争议。本研究旨在评估术前使用卢戈溶液对接受全甲状腺切除术的巴塞杜氏病患者甲状腺血管化和手术发病率的影响:在这项单中心、单盲试验中,56名接受甲状腺全切除术的巴塞杜氏病患者被随机分配到术前接受7天鲁戈尔治疗(鲁戈尔+组,29人)或不接受鲁戈尔治疗(LS-组,27人)。手术前 8 天(T0)和手术当天(T1)收集术前激素和用于评估甲状腺血管的彩色多普勒超声数据。主要结果是术中和术后失血量。次要结果包括手术时间、甲状腺功能、发病率、血管化程度以及最终病理检查时的微血管密度:结果:LS+组和LS-组在T0时的人口统计学、术前激素或超声数据均无差异。T1时,与T0值相比,LS+组游离三碘甲状腺原氨酸(FT3)和游离甲状腺素(FT4)水平明显降低,而LS-组无此变化。两组患者在 T0 和 T1 期间的超声血管造影结果均无差异,组织学结果也无差异。LS+组和LS-组在术中/术后失血量(中位数分别为80.5毫升和94毫升)、手术时间(两组均为75分钟)或术后发病率方面均无明显差异:结论:卢戈溶液可明显降低接受手术治疗巴塞杜氏病患者的FT3和FT4水平,但不会减少术中/术后失血量、甲状腺血管形成、手术持续时间或术后发病率:NCT05784792 (https://www.clinicaltrials.gov)。
{"title":"Role of Lugol solution before total thyroidectomy for Graves' disease: randomized clinical trial.","authors":"Donatella Schiavone, Filippo Crimì, Giulio Cabrelle, Gianmaria Pennelli, Diana Sacchi, Caterina Mian, Francesca Torresan, Maurizio Iacobone","doi":"10.1093/bjs/znae196","DOIUrl":"10.1093/bjs/znae196","url":null,"abstract":"<p><strong>Background: </strong>Lugol solution is often administered to patients with Graves' disease before surgery. The aim is to reduce thyroid vascularization and surgical morbidity, but its real effectiveness remains controversial. The present study was designed to evaluate the effects of preoperative Lugol solution on thyroid vascularization and surgical morbidity in patients with Graves' disease undergoing total thyroidectomy.</p><p><strong>Methods: </strong>Fifty-six patients undergoing total thyroidectomy for Graves' disease were randomly assigned to receive 7 days of Lugol treatment (Lugol+ group, 29) or no Lugol treatment (LS- group, 27) before surgery in this single-centre and single-blinded trial. Preoperative hormone and colour Doppler ultrasonographic data for assessing thyroid vascularization were collected 8 days before surgery (T0) and on the day of surgery (T1). The primary outcome was intraoperative and postoperative blood loss. Secondary outcomes included duration of surgery, thyroid function, morbidity, vascularization, and microvessel density at final pathology.</p><p><strong>Results: </strong>No differences in demographic, preoperative hormone or ultrasonographic data were found between LS+ and LS- groups at T0. At T1, free tri-iodothyronine (FT3) and free thyroxine (FT4) levels were significantly reduced compared with T0 values in the LS+ group, whereas no such variation was observed in the LS- group. No differences between T0 and T1 were found for ultrasonographic vascularization in either group, nor did the histological findings differ. There were no significant differences between the LS+ and LS- groups concerning intraoperative/postoperative blood loss (median 80.5 versus 94 ml respectively), duration of surgery (75 min in both groups) or postoperative morbidity.</p><p><strong>Conclusion: </strong>Lugol solution significantly reduces FT3 and FT4 levels in patients undergoing surgery for Graves' disease, but does not decrease intraoperative/postoperative blood loss, thyroid vascularization, duration of surgery or postoperative morbidity.</p><p><strong>Registration number: </strong>NCT05784792 (https://www.clinicaltrials.gov).</p>","PeriodicalId":136,"journal":{"name":"British Journal of Surgery","volume":null,"pages":null},"PeriodicalIF":8.6,"publicationDate":"2024-08-02","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141915582","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Laparoscopic versus open right hepatectomy for colorectal liver metastases after portal vein embolization: international multicentre study. 门静脉栓塞术后结直肠肝转移的腹腔镜与开腹右肝切除术:国际多中心研究。
IF 8.6 1区 医学 Q1 SURGERY Pub Date : 2024-08-02 DOI: 10.1093/bjs/znae181
Emre Bozkurt, Jasper P Sijberden, Serena Langella, Federica Cipriani, Francesc Collado-Roura, Victoria Morrison-Jones, Burak Görgec, Gabriel Zozaya, Jacopo Lanari, Davit Aghayan, Celine De Meyere, David Fuks, Giuseppe Zimmiti, Benedetto Ielpo, Mikhail Efanov, Robert P Sutcliffe, Nadia Russolillo, Miquel Gomez-Artacho, Francesca Ratti, Mathieu D'Hondt, Bjørn Edwin, Umberto Cillo, Fernando Rotellar, Marc G Besselink, John N Primrose, Santi Lopez-Ben, Luca A Aldrighetti, Alessandro Ferrero, Mohammad Abu Hilal

Background: Laparoscopic liver surgery is increasingly used for more challenging procedures. The aim of this study was to assess the feasibility and oncological safety of laparoscopic right hepatectomy for colorectal liver metastases after portal vein embolization.

Methods: This was an international retrospective multicentre study of patients with colorectal liver metastases who underwent open or laparoscopic right and extended right hepatectomy after portal vein embolization between 2004 and 2020. The perioperative and oncological outcomes for patients who underwent laparoscopic and open approaches were compared using propensity score matching.

Results: Of 338 patients, 84 patients underwent a laparoscopic procedure and 254 patients underwent an open procedure. Patients in the laparoscopic group less often underwent extended right hepatectomy (18% versus 34.6% (P = 0.004)), procedures in the setting of a two-stage hepatectomy (42% versus 65% (P < 0.001)), and major concurrent procedures (4% versus 16.1% (P = 0.003)). After propensity score matching, 78 patients remained in each group. The laparoscopic approach was associated with longer operating and Pringle times (330 versus 258.5 min (P < 0.001) and 65 versus 30 min (P = 0.001) respectively) and a shorter length of stay (7 versus 8 days (P = 0.011)). The R0 resection rate was not different (71% for the laparoscopic approach versus 60% for the open approach (P = 0.230)). The median disease-free survival was 12 (95% c.i. 10 to 20) months for the laparoscopic approach versus 20 (95% c.i. 13 to 31) months for the open approach (P = 0.145). The median overall survival was 28 (95% c.i. 22 to 48) months for the laparoscopic approach versus 42 (95% c.i. 35 to 52) months for the open approach (P = 0.614).

Conclusion: The advantages of a laparoscopic over an open approach for (extended) right hepatectomy for colorectal liver metastases after portal vein embolization are limited.

背景:腹腔镜肝脏手术越来越多地用于更具挑战性的手术。本研究旨在评估门静脉栓塞术后腹腔镜右肝切除术治疗结直肠肝转移瘤的可行性和肿瘤安全性:这是一项国际多中心回顾性研究,研究对象是2004年至2020年间接受门静脉栓塞术后开腹或腹腔镜右肝切除术和右肝扩大切除术的结直肠肝转移患者。采用倾向评分匹配法比较了腹腔镜和开腹手术患者的围手术期和肿瘤学结果:在 338 名患者中,84 名患者接受了腹腔镜手术,254 名患者接受了开腹手术。腹腔镜组患者较少接受扩大右肝切除术(18% 对 34.6% (P = 0.004))、两期肝切除术(42% 对 65% (P < 0.001))和主要并发症手术(4% 对 16.1% (P = 0.003))。经过倾向评分匹配后,每组仍有78名患者。腹腔镜方法的手术时间和普林格尔时间更长(分别为330分钟对258.5分钟(P < 0.001)和65分钟对30分钟(P = 0.001)),住院时间更短(7天对8天(P = 0.011))。R0切除率没有差异(腹腔镜方法为71%,开腹方法为60%(P = 0.230))。腹腔镜方法的中位无病生存期为12个月(95% c.i.10至20个月),而开腹方法为20个月(95% c.i.13至31个月)(P = 0.145)。腹腔镜方法的中位总生存期为28(95% c.i.22至48)个月,而开腹方法为42(95% c.i.35至52)个月(P = 0.614):结论:在门静脉栓塞术后进行结直肠肝转移(扩大)右肝切除术时,腹腔镜方法比开腹方法的优势有限。
{"title":"Laparoscopic versus open right hepatectomy for colorectal liver metastases after portal vein embolization: international multicentre study.","authors":"Emre Bozkurt, Jasper P Sijberden, Serena Langella, Federica Cipriani, Francesc Collado-Roura, Victoria Morrison-Jones, Burak Görgec, Gabriel Zozaya, Jacopo Lanari, Davit Aghayan, Celine De Meyere, David Fuks, Giuseppe Zimmiti, Benedetto Ielpo, Mikhail Efanov, Robert P Sutcliffe, Nadia Russolillo, Miquel Gomez-Artacho, Francesca Ratti, Mathieu D'Hondt, Bjørn Edwin, Umberto Cillo, Fernando Rotellar, Marc G Besselink, John N Primrose, Santi Lopez-Ben, Luca A Aldrighetti, Alessandro Ferrero, Mohammad Abu Hilal","doi":"10.1093/bjs/znae181","DOIUrl":"10.1093/bjs/znae181","url":null,"abstract":"<p><strong>Background: </strong>Laparoscopic liver surgery is increasingly used for more challenging procedures. The aim of this study was to assess the feasibility and oncological safety of laparoscopic right hepatectomy for colorectal liver metastases after portal vein embolization.</p><p><strong>Methods: </strong>This was an international retrospective multicentre study of patients with colorectal liver metastases who underwent open or laparoscopic right and extended right hepatectomy after portal vein embolization between 2004 and 2020. The perioperative and oncological outcomes for patients who underwent laparoscopic and open approaches were compared using propensity score matching.</p><p><strong>Results: </strong>Of 338 patients, 84 patients underwent a laparoscopic procedure and 254 patients underwent an open procedure. Patients in the laparoscopic group less often underwent extended right hepatectomy (18% versus 34.6% (P = 0.004)), procedures in the setting of a two-stage hepatectomy (42% versus 65% (P < 0.001)), and major concurrent procedures (4% versus 16.1% (P = 0.003)). After propensity score matching, 78 patients remained in each group. The laparoscopic approach was associated with longer operating and Pringle times (330 versus 258.5 min (P < 0.001) and 65 versus 30 min (P = 0.001) respectively) and a shorter length of stay (7 versus 8 days (P = 0.011)). The R0 resection rate was not different (71% for the laparoscopic approach versus 60% for the open approach (P = 0.230)). The median disease-free survival was 12 (95% c.i. 10 to 20) months for the laparoscopic approach versus 20 (95% c.i. 13 to 31) months for the open approach (P = 0.145). The median overall survival was 28 (95% c.i. 22 to 48) months for the laparoscopic approach versus 42 (95% c.i. 35 to 52) months for the open approach (P = 0.614).</p><p><strong>Conclusion: </strong>The advantages of a laparoscopic over an open approach for (extended) right hepatectomy for colorectal liver metastases after portal vein embolization are limited.</p>","PeriodicalId":136,"journal":{"name":"British Journal of Surgery","volume":null,"pages":null},"PeriodicalIF":8.6,"publicationDate":"2024-08-02","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11319932/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141970151","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Corrigendum: Defining standards and core outcomes for clinical trials in prehabilitation for colorectal surgery (DiSCO): modified Delphi methodology to achieve patient and healthcare professional consensus. 更正:确定结直肠手术前康复(DiSCO)临床试验的标准和核心结果:改良德尔菲法达成患者和医护人员共识。
IF 8.6 1区 医学 Q1 SURGERY Pub Date : 2024-08-02 DOI: 10.1093/bjs/znae201
{"title":"Corrigendum: Defining standards and core outcomes for clinical trials in prehabilitation for colorectal surgery (DiSCO): modified Delphi methodology to achieve patient and healthcare professional consensus.","authors":"","doi":"10.1093/bjs/znae201","DOIUrl":"10.1093/bjs/znae201","url":null,"abstract":"","PeriodicalId":136,"journal":{"name":"British Journal of Surgery","volume":null,"pages":null},"PeriodicalIF":8.6,"publicationDate":"2024-08-02","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11295327/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141873661","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Management of subcutaneous abscesses: prospective cross-sectional study (MAGIC). 皮下脓肿的治疗:前瞻性横断面研究(MAGIC)。
IF 8.6 1区 医学 Q1 SURGERY Pub Date : 2024-08-02 DOI: 10.1093/bjs/znae162
{"title":"Management of subcutaneous abscesses: prospective cross-sectional study (MAGIC).","authors":"","doi":"10.1093/bjs/znae162","DOIUrl":"10.1093/bjs/znae162","url":null,"abstract":"","PeriodicalId":136,"journal":{"name":"British Journal of Surgery","volume":null,"pages":null},"PeriodicalIF":8.6,"publicationDate":"2024-08-02","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11334058/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142003177","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
期刊
British Journal of Surgery
全部 Acc. Chem. Res. ACS Applied Bio Materials ACS Appl. Electron. Mater. ACS Appl. Energy Mater. ACS Appl. Mater. Interfaces ACS Appl. Nano Mater. ACS Appl. Polym. Mater. ACS BIOMATER-SCI ENG ACS Catal. ACS Cent. Sci. ACS Chem. Biol. ACS Chemical Health & Safety ACS Chem. Neurosci. ACS Comb. Sci. ACS Earth Space Chem. ACS Energy Lett. ACS Infect. Dis. ACS Macro Lett. ACS Mater. Lett. ACS Med. Chem. Lett. ACS Nano ACS Omega ACS Photonics ACS Sens. ACS Sustainable Chem. Eng. ACS Synth. Biol. Anal. Chem. BIOCHEMISTRY-US Bioconjugate Chem. BIOMACROMOLECULES Chem. Res. Toxicol. Chem. Rev. Chem. Mater. CRYST GROWTH DES ENERG FUEL Environ. Sci. Technol. Environ. Sci. Technol. Lett. Eur. J. Inorg. Chem. IND ENG CHEM RES Inorg. Chem. J. Agric. Food. Chem. J. Chem. Eng. Data J. Chem. Educ. J. Chem. Inf. Model. J. Chem. Theory Comput. J. Med. Chem. J. Nat. Prod. J PROTEOME RES J. Am. Chem. Soc. LANGMUIR MACROMOLECULES Mol. Pharmaceutics Nano Lett. Org. Lett. ORG PROCESS RES DEV ORGANOMETALLICS J. Org. Chem. J. Phys. Chem. J. Phys. Chem. A J. Phys. Chem. B J. Phys. Chem. C J. Phys. Chem. Lett. Analyst Anal. Methods Biomater. Sci. Catal. Sci. Technol. Chem. Commun. Chem. Soc. Rev. CHEM EDUC RES PRACT CRYSTENGCOMM Dalton Trans. Energy Environ. Sci. ENVIRON SCI-NANO ENVIRON SCI-PROC IMP ENVIRON SCI-WAT RES Faraday Discuss. Food Funct. Green Chem. Inorg. Chem. Front. Integr. Biol. J. Anal. At. Spectrom. J. Mater. Chem. A J. Mater. Chem. B J. Mater. Chem. C Lab Chip Mater. Chem. Front. Mater. Horiz. MEDCHEMCOMM Metallomics Mol. Biosyst. Mol. Syst. Des. Eng. Nanoscale Nanoscale Horiz. Nat. Prod. Rep. New J. Chem. Org. Biomol. Chem. Org. Chem. Front. PHOTOCH PHOTOBIO SCI PCCP Polym. Chem.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1